Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Oligomeric peptides LLRLTDL and GYALPCDCL alleviate obesity through HO-1/Nrf2-dependent pathways in high-fat diet-induced mice.

Marasinghe CK., Dayarathne LA., Suryaningtyas IT., Jasmadi, Je JY.

Animal Study on Chronic Inflammation, published in J Nutr Biochem (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Nutr Biochem (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41921669
DOI
10.1016/j.jnutbio.2026.110360

Abstract (original English)

The potential antiobesity, anti-inflammatory, and antioxidative stress properties of ark shell-derived LLRLTDL (Bu1) and GYALPCDCL (Bu2) peptides were comprehensively investigated. In bone marrow-derived mesenchymal stem cells, both peptides demonstrated significant antiadipogenic effects by downregulating key adipogenic transcription factors, including peroxisome proliferator-activated receptor gamma, CCAAT/enhancer-binding protein alpha, and sterol regulatory element-binding protein 1 and their downstream adipocyte-specific genes, including adipocyte fatty acid-binding protein 2, fatty acid synthase, and lipoprotein lipase. Mechanistically, Bu1 and Bu2 promoted lipolysis through the activation of AMP-activated protein kinase and hormone-sensitive lipase. These peptides also exhibited potent antioxidative stress activity by suppressing reactive oxygen species generation and activating the heme oxygenase-1/Nrf2 signaling pathway, as confirmed through heme oxygenase-1 small interfering RNA silencing. In addition, Bu1 and Bu2 demonstrated robust anti-inflammatory effects by reducing proinflammatory cytokine production and inhibiting mitogen-activated protein kinase signaling pathways. These findings were corroborated in a high-fat diet-induced mouse model, where oral administration of Bu1 and Bu2 resulted in significant reductions in body weight, weight gain, and adipose tissue a

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsNF-E2-Related Factor 2Diet, High-FatObesityMaleHeme Oxygenase-1MiceSignal TransductionMice, Inbred C57BLOxidative Stress

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research